Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the treatment of infectious diseases and for use as vaccine adjuvants. The company initiated a research program employing its gene silencing technologies to suppress the production of proteins associated with diseases by targeting RNA. It designs and formulates proprietary TLR agonists and antagonists to modulate immune responses. The lead products in the pipeline are IMO-2125, IMO-8400, IMO-9200, and antagonists of TLRs 7, 8, and 9 for the treatment of lupus. Idera is headquartered in Massachusetts, the US.

Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
Merger 14
BioCryst Pharma and Idera Pharma to Merge 14
Licensing Agreements 16
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 16
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 17
Equity Offering 18
Idera Pharma Prices Public Offering of Shares for USD50 Million 18
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 20
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 22
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 24
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 25
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 27
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 29
Idera Pharmaceuticals Inc - Key Competitors 30
Idera Pharmaceuticals Inc - Key Employees 31
Idera Pharmaceuticals Inc - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
May 09, 2018: Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 07, 2018: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 35
Nov 06, 2017: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 37
Aug 07, 2017: Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results 40
May 04, 2017: Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 43
Mar 15, 2017: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 46
Corporate Communications 49
Apr 23, 2018: Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors 49
Oct 24, 2017: Idera Pharmaceuticals Provides Corporate Governance Update 50
Apr 18, 2017: Idera Pharmaceuticals Announces Organizational Update 51
Legal and Regulatory 52
Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 52
Product News 53
11/09/2017: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) 53
04/11/2017: Idera Pharmaceuticals Advances Investigational Treatment Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma 55
02/06/2017: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 57
Product Approvals 58
Nov 29, 2017: U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma 58
Jun 22, 2017: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 59
Clinical Trials 61
Apr 17, 2018: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting 61
Mar 01, 2018: Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) 62
Sep 10, 2017: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy 63
Sep 08, 2017: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory 65
Apr 05, 2017: Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting 66
Feb 24, 2017: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 68
Other Significant Developments 69
Jan 05, 2018: Idera Pharmaceuticals Provides 2018 Update and Outlook 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List Of Tables

List of Tables
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
BioCryst Pharma and Idera Pharma to Merge 14
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 16
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 17
Idera Pharma Prices Public Offering of Shares for USD50 Million 18
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 20
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 22
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 24
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 25
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 27
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 29
Idera Pharmaceuticals Inc, Key Competitors 30
Idera Pharmaceuticals Inc, Key Employees 31
Idera Pharmaceuticals Inc, Other Locations 32

List Of Figures

List of Figures
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops

USD 250 View Report

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Pivot Pharmaceuticals Inc (PVOTF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pivot Pharmaceuticals Inc (Pivot Pharmaceuticals), formerly Neurokine Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of cannabinoid based neutraceutical and pharmaceutical products. The companys major

USD 250 View Report

Fog Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fog Pharmaceuticals Inc (Fog Pharmaceuticals) is a clinical-stage biotechnology company that discovers and develops next-generation peptide inhibitors that target traditionally undruggable intracellular protein-protein interactions. The company develops cell-penetrating miniproteins (CPMPs),

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available